Skip to main content
Top
Published in: Supportive Care in Cancer 10/2006

01-10-2006 | Editorial

Placing quality of life assessments on oncologists’ agenda

Author: Luzia Travado

Published in: Supportive Care in Cancer | Issue 10/2006

Login to get access

Excerpt

The last two decades have witnessed a dramatic growth in interest in the assessment of quality of life (QoL) in both oncology research and practice [13]. The availability of reliable, cancer-specific instruments for use with cancer patients (e.g., EORTC QLQ-C30, FACT), the changing attitude towards a more biopsychosocial oriented model of clinical practice, as well as the demand by patients themselves and consumer advocacy organizations to address their psychosocial needs as part of quality cancer care have served to bring QoL assessment into the oncologists’ agenda. Side effects of treatments have long been a concern for cancer clinicians and were traditionally assessed as a way to understand the impact of therapy and monitor (and when necessary manage) its efficacy. But the QoL concept has evolved from a largely unidimensional biological construct, focused basically on physical symptoms and functional ability, to a multidimensional construct that includes in its definition assessment of other dimensions such as psychological well-being, social functioning, spirituality, etc. [46]. Patient’s subjective perceptions of their QoL have come to play an important role as medicine has become more patient-centered and patients have become more educated and informed about their illness and treatment options. Increasingly partners in the clinical decision-making process, patients and clinicians strive to balance the various demands of a given therapy with the personal preferences of the patient in choosing a specific treatment. It is no longer acceptable to pursue “blind survival at all costs” (at the expense of QoL). The European Cancer Patient Coalition (http://​www.​ecpc-online.​org) motto of Nothing About Us Without Us illustrates how much advocacy organizations emphasize the importance of bringing patients’ views into the decision arena, whether it be the singular patient perspective and participating–partnering with clinicians in all decisions affecting their well-being or as Patients’ Organizations (Associations or Coalitions) demanding the opportunity to participate in policy-making. …
Literature
1.
go back to reference Rowland J (1997) Outcomes assessment: cancer-specific quality-of-life measures: beyond the research setting. American Society of Clinical Oncology (ASCO) Educational Book, 33rd Annual Meeting, May 1997 Rowland J (1997) Outcomes assessment: cancer-specific quality-of-life measures: beyond the research setting. American Society of Clinical Oncology (ASCO) Educational Book, 33rd Annual Meeting, May 1997
2.
go back to reference Gunnars B, Nygren P, Glimelius B, SBU-group (2001) Assessment of quality of life during chemotherapy (review). Acta Oncol 40:175–184PubMedCrossRef Gunnars B, Nygren P, Glimelius B, SBU-group (2001) Assessment of quality of life during chemotherapy (review). Acta Oncol 40:175–184PubMedCrossRef
3.
go back to reference Jacobsen PB, Davis K, Cella D (2002) Assessing quality of life in research and clinical practice. Oncology 16(9 suppl):133–139PubMed Jacobsen PB, Davis K, Cella D (2002) Assessing quality of life in research and clinical practice. Oncology 16(9 suppl):133–139PubMed
4.
go back to reference Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef
5.
go back to reference Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed
6.
go back to reference Stewart A, Hays R, Ware J (1988) The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 26:724–735PubMedCrossRef Stewart A, Hays R, Ware J (1988) The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 26:724–735PubMedCrossRef
7.
go back to reference Davis K, Cella D (2002) Assessing quality of life in Oncology clinical practice: a review of barriers and critical success factors. J Clin Outcomes Manage 9:327–332 Davis K, Cella D (2002) Assessing quality of life in Oncology clinical practice: a review of barriers and critical success factors. J Clin Outcomes Manage 9:327–332
8.
go back to reference Keibert G, Wait S, Bernhard J et al (2001) Practice and policy of measuring quality of life and health economics in cancer clinical trials: a survey among co-operative trial groups. Qual Life Res 9:1080–1973 Keibert G, Wait S, Bernhard J et al (2001) Practice and policy of measuring quality of life and health economics in cancer clinical trials: a survey among co-operative trial groups. Qual Life Res 9:1080–1973
9.
go back to reference Sloan JA, Cella D, Frost M et al (2002) Assessing clinical significance in measuring oncology patients quality of life: introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc 77:367–370PubMed Sloan JA, Cella D, Frost M et al (2002) Assessing clinical significance in measuring oncology patients quality of life: introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc 77:367–370PubMed
10.
go back to reference Guyatt GH, Osoba D, Wu AW et al (2002) Methods to explain the clinical significance of health status measures. Mayo Clin Proc 77:371–383PubMed Guyatt GH, Osoba D, Wu AW et al (2002) Methods to explain the clinical significance of health status measures. Mayo Clin Proc 77:371–383PubMed
11.
go back to reference Cella D, Bullinger M, Scott C et al (2002) Group versus individual approaches to understanding the clinical significance of differences or changes in quality of life. Mayo Clin Proc 77:384–392PubMed Cella D, Bullinger M, Scott C et al (2002) Group versus individual approaches to understanding the clinical significance of differences or changes in quality of life. Mayo Clin Proc 77:384–392PubMed
12.
go back to reference Sloan JA, Aaronson N, Cappelleri JC (2002) Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc 77:479–487PubMed Sloan JA, Aaronson N, Cappelleri JC (2002) Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc 77:479–487PubMed
13.
go back to reference Frost MH, Bonomi AE, Ferrans CE et al (2002) Patient, clinician, and population perspectives on determining the clinical significance of quality-of-life scores. Mayo Clin Proc 77:488–494 Frost MH, Bonomi AE, Ferrans CE et al (2002) Patient, clinician, and population perspectives on determining the clinical significance of quality-of-life scores. Mayo Clin Proc 77:488–494
14.
go back to reference Sprangers MAG, Moinpour CM, Moynihan TJ et al (2002) Assessing meaningful change in quality of life over time: a user’s guide for clinicians. Mayo Clin Proc 77:561–571PubMed Sprangers MAG, Moinpour CM, Moynihan TJ et al (2002) Assessing meaningful change in quality of life over time: a user’s guide for clinicians. Mayo Clin Proc 77:561–571PubMed
15.
go back to reference Symonds T, Berzon R, Marquis P et al (2002) The clinical significance of quality-of-life results: practical considerations for specific audiences. Mayo Clin Proc 77:572–583PubMedCrossRef Symonds T, Berzon R, Marquis P et al (2002) The clinical significance of quality-of-life results: practical considerations for specific audiences. Mayo Clin Proc 77:572–583PubMedCrossRef
16.
go back to reference Detmar SB et al (2002) Health-related quality-of-life assessments and patient–physician communication. A randomized controlled trial. JAMA 288:3027–3034PubMedCrossRef Detmar SB et al (2002) Health-related quality-of-life assessments and patient–physician communication. A randomized controlled trial. JAMA 288:3027–3034PubMedCrossRef
17.
go back to reference Grassi L, Travado L, Gil F, Campos R, Lluch P, Baile W (2005) A communication intervention for training southern European oncologists to recognize psychosocial morbidity in cancer patients. I. development of the model and preliminary results on physicians’ satisfaction. J Cancer Educ 20:79–84PubMedCrossRef Grassi L, Travado L, Gil F, Campos R, Lluch P, Baile W (2005) A communication intervention for training southern European oncologists to recognize psychosocial morbidity in cancer patients. I. development of the model and preliminary results on physicians’ satisfaction. J Cancer Educ 20:79–84PubMedCrossRef
Metadata
Title
Placing quality of life assessments on oncologists’ agenda
Author
Luzia Travado
Publication date
01-10-2006
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 10/2006
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-006-0130-x

Other articles of this Issue 10/2006

Supportive Care in Cancer 10/2006 Go to the issue

Letter to the Editor

Letter to the Editor

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine